Skip to main content
SpringerLink
Log in

Monoclonal Antibody Therapy for B-Cell Lymphoma

  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Treatment strategies and outcomes for patients with non-Hodgkin’s lymphoma (NHL) are undergoing rapid and important evolution. We have recently witnessed the advent of novel targeted therapies, such as gene therapies, active immunotherapies, antisense therapies, new small molecules and biologicals, and monoclonal antibodies (MoAbs). The first MoAb approved for the treatment of cancer, rituximab, was approved in 1997 and has been rapidly incorporated into treatment regimens for NHL. In a randomized trial in combination with CHOP chemotherapy (cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone), rituximab showed superiority to CHOP for patients with diffuse large cell NHL (DLCL).The rituximab + CHOP combination has become the gold standard for frontline therapy for DLCL and has shown significant activity in the management of follicular NHL. In February 2002, the first radioimmunotherapeutic agent for the treatment of cancer, ibritumomab tiuxetan (Zevalin), was approved. Ibritumomab tiuxetan, an yttrium-labeled antibody used in conjunction with rituximab, has significant activity in follicular and transformed NHL. Use of rituximab has proved that antibodies are safe and active even as single agents.The results have helped dispel the negativity and biases resulting from many years of disappointing results in this important area of research. Results with rituximab have opened the doors to continued research and have provided the impetus necessary for renewed enthusiasm and optimism in continuing the search for curative regimens for patients with NHL.Int J Hematol. 2002;76:385-393.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dillman RO. Antibodies as cytotoxic therapy.J Clin Oncol. 1994; 12:1497–1515.

    Article  PubMed  CAS  Google Scholar 

  2. Kohler G, Milstein C. Continuous cultures of fused secreting antibody of redefined specificity.Nature. 1975;256:495–497.

    Article  PubMed  CAS  Google Scholar 

  3. Grillo-López AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.Semin Oncol. 1999;26(suppl 14):66–73.

    PubMed  Google Scholar 

  4. Grillo-López AJ. The important role of monoclonal antibodies in the treatment of non-Hodgkin’s lymphomas.Oncol Spectr. 2001;2: 700–705.

    Google Scholar 

  5. World Health Organization.WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979:48.

    Google Scholar 

  6. Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982;5:649–655.

    Article  PubMed  CAS  Google Scholar 

  7. Miller R, Maloney D, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.N Engl J Med. 1982;306:517–522.

    Article  PubMed  CAS  Google Scholar 

  8. Scheinberg D, Straus D, Yeh S, et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin’s lymphoma: effects of tumor burden and antigen expression.J Clin Oncol. 1990;8:792–803.

    Article  PubMed  CAS  Google Scholar 

  9. Hekman A, Honselaar A, Vuist WMJ, et al. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody.Cancer Immunol Immunother. 1991;32:364–372.

    Article  PubMed  CAS  Google Scholar 

  10. Press O,Appelbaum F, Ledbetter J, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas.Blood. 1987; 69:584–591.

    Article  PubMed  CAS  Google Scholar 

  11. Davis TA, Kaminski MS, Leonard JP, et al. Results of a randomized trial of Bexxar (tositumomab and iodine I 131 tositumomab) vs unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin’s lymphoma [abstract].Blood. 2001;98:843a. Abstract 3503.

    Google Scholar 

  12. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma.Ann Oncol. 1998;9:995–1001.

    Article  PubMed  CAS  Google Scholar 

  13. Piro LD, White CA, Grillo-López AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma.Ann Oncol. 1999;10:655–661.

    Article  PubMed  CAS  Google Scholar 

  14. Grillo-López AJ. Rituximab: an insider’s historical perspective.Semin Oncol. 2000;27(suppl 12):9–16.

    PubMed  Google Scholar 

  15. Anderson DR, Grillo-López A, Varns C, et al. Targeting cytotoxic immunotherapy: targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin’s B-cell lymphoma.Biochem Soc Trans. 1997;25: 705–708.

    Article  PubMed  CAS  Google Scholar 

  16. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.Blood. 1994;84:2457–2466.

    Article  PubMed  CAS  Google Scholar 

  17. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rit-uximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma.Blood. 1997;90: 2188–2195.

    Article  PubMed  CAS  Google Scholar 

  18. Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphoma.J Clin Oncol. 1999;17:1244–1253.

    Article  PubMed  CAS  Google Scholar 

  19. Grillo-López AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: importance of “normal” lymph node size and correlations with response rates.Ann Oncol. 2000;11:399–408.

    Article  PubMed  Google Scholar 

  20. McLaughlin P, Grillo-López AJ, Link BK, et al. Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833.

    Article  PubMed  CAS  Google Scholar 

  21. Davis TA, White CA, Grillo-López AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab.J Clin Oncol. 1999;17:1851–1857.

    Article  PubMed  CAS  Google Scholar 

  22. Colombat P, Salles G, Brousse N, et al. Rituximab (anti CD-20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.Blood. 2001;97:101–106.

    Article  PubMed  CAS  Google Scholar 

  23. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin’s lymphoma.Blood. 2000;95:3052–3056.

    Article  PubMed  CAS  Google Scholar 

  24. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab as first line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma [abstract].Proc Am Soc Clin Oncol. 2001;20: 294a. Abstract 1175.

    Google Scholar 

  25. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low grade B-cell lymphoma with the combination of chimeric anti-CD-20 monoclonal antibody and CHOP chemotherapy.J Clin Oncol. 1999;17:268–276.

    Article  PubMed  CAS  Google Scholar 

  26. Czuczman MS, Grillo-López AJ, White CA, et al. Progression free survival after six years (median) follow-up of the first clinical trial of rituximab/CHOP chemoimmunotherapy [abstract].Blood. 2001;98:601a. Abstract 2519.

    Google Scholar 

  27. Vose JM, Link BK, Grossboard ML, et al. Phase II Study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma.J Clin Oncol. 2001;19:389–397.

    Article  PubMed  CAS  Google Scholar 

  28. Coiffier B, Lepage E, Briére J, et al. CHOP chemotherapy plus rit-uximab compared with chop alone in elderly patients with diffuse large B-cell lymphoma.N Engl J Med. 2002;346:235–242.

    Article  PubMed  CAS  Google Scholar 

  29. Czuczman MS, Fallon A, Mohr A, et al. Phase II study of rituximab plus fludarabine in patients with low-grade lymphoma: final report [abstract].Blood. 2001;98:601a. Abstract 2518.

    Google Scholar 

  30. Herold M, Fielder F, Pasold R, et al. Efficacy and toxicity of rituximab plus mitoxantrone, chlorambucil, and prednisone (MCP) versus MCP alone in advanced indolent NHL- interim results of a clinical phase III study of the East German Study Group Hematology/Oncology [abstract].Blood. 2001;98:601a. Abstract 2521.

    Google Scholar 

  31. McLaughlin P, Hagemeister FB, Rodriguez MA, et al. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.Semin Oncol. 2000;27(suppl 12):37–41.

    PubMed  CAS  Google Scholar 

  32. Cabanillas F, McLaughlin P, Hagemeister F, et al. Molecular responses with FND + Rituxan chemoimmunotherapy for stage IV indolent follicular non-Hodgkin’s lymphoma [abstract].Blood. 2000;96:331a. Abstract 1429.

    Google Scholar 

  33. Wilson WH, Pittaluga S, O’Connor P, et al. Rituximab may overcome BCL-2 associated chemotherapy resistance in untreated diffuse large B-cell lymphomas [abstract].Blood. 2001;98:343a. Abstract 1447.

    Article  Google Scholar 

  34. Wilson WH, Frankel SR, Drbohlav N, et al. Phase II study of dose- adjusted EPOCH-rituximab in untreated high risk large B-cell lymphomas [abstract].Proc Am Soc Clin Oncol. 2001;20:290a. Abstract 1158.

    Google Scholar 

  35. Jost LM, Jermann M, Stahel RA, et al. Rituximab-EPOCH—an effective salvage regime for relapsed, refractory, or transformed B-cell lymphoma: results of a phase II study [abstract].Proc Am Soc Clin Oncol. 2001;20:290a. Abstract 1157.

    Google Scholar 

  36. Kewalramani T, Zelenetz A, Bertino J, et al. Rituximab significantly increases the complete response rate in patients with relapsed or primary DLBCL receiving ICE as second-line therapy (SLT) [abstract].Blood. 2001;98:346a. Abstract 1459.

    Google Scholar 

  37. Younes A, McLaughlin P, Hagemeister FB, et al. High response rate and complete remission rate achieved by adding rituximab to Taxol plus topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma [abstract].Blood. 2001;98:345a. Abstract 1456.

    Google Scholar 

  38. Davis TA, Maloney DG, Grillo-López AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with rituximab and interferon-α-2a.Clin Cancer Res. 2000;6:2644–2652.

    PubMed  CAS  Google Scholar 

  39. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma.J Clin Oncol. 1998;16:3257–3263.

    Article  PubMed  CAS  Google Scholar 

  40. Link BK, Wang H, Byrd JC, et al. Phase I study of HuD10 monoclonal antibody (Remitogen) in patients with B-cell lymphoma [abstract].Proc Am Soc Clin Oncol. 2001;20:284a. Abstract 1135.

    Google Scholar 

  41. Link BK, Wang H, Byrd JC, et al. Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen (Hu1D10) [abstract].Blood. 2001;98. Abstract 4703.

  42. Link BK, Kahl B, Czuczman M, et al. A phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma [abstract].Blood. 2001;98. Abstract 2450.

    Article  Google Scholar 

  43. Leonard JP, Coleman M, Schuster MW, et al. Epratuzumab, a new anti-CD22-humanized monoclonal antibody for the therapy of non-Hodgkin’s lymphoma (NHL): phase I/II trials results [abstract].Blood. 1999;94(suppl 1):92a. Abstract 404.

    Google Scholar 

  44. Leonard JP, Coleman M, Chadburn A, et al. Epratuzumab (HLL2, anti-CD22 humanized monoclonal antibody) is an active and well-tolerated therapy for refractory/relapsed diffuse large B-cell non-Hodgkin’s lymphoma [abstract].Blood.2000;96:578a.Abstract 2482.

    Google Scholar 

  45. Leonard JP, Coleman M, Matthews JC, et al. Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin’s lymphoma: preliminary response data.Proc Am Soc Clin Oncol. 2001;20. Abstract 1060.

    Google Scholar 

  46. Grillo-López AJ, ed. Monoclonal antibodies in the treatment of hematologic malignancies.Curr Pharm Biotechnol. 2001;2(theme issue).

  47. Kreitman RJ. Toxin labeled monoclonal antibodies.Curr Pharm Biotechnol. 2001;2:313–325.

    Article  PubMed  CAS  Google Scholar 

  48. Meredith RF, Knox SJ. Radioimmunotherapy of B-Cell NHL.Curr Pharm Biotechnol. 2001;2:327–339.

    Article  PubMed  CAS  Google Scholar 

  49. Hajjar G, Sharkey RM, Burton J, et al. Interim results of a phase I/ II radioimmunotherapy trial in relapsed/refractory non-Hodgkin’s lymphoma patients given90yttrium labeled anti-CD22 humanized monoclonal antibody, epratuzumab [abstract].Blood. 2000;96. Abstract 2560.

    Google Scholar 

  50. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen.Cancer Res. 1980;40:3147–3154.

    PubMed  CAS  Google Scholar 

  51. Gockerman J, Gregory S, Harwood S, et al. Interim efficacy results of Bexxar in a large multicenter open access study [abstract].J Clin Oncol. 2001. Abstract 1138.

  52. Fehrenbacher L, Radford J, Kaminski M, et al. Patient-specific dosing of Bexxar is associated with tolerable and predictable hematologic toxicity in patients with known hematologic risk factors [abstract].J Clin Oncol. 2001;20:287a. Abstract 1144.

    Google Scholar 

  53. Kaminsky MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I131 tositumomab for chemotherapy refractory low grade or transformed low grade B-cell non-Hodgkin’s lymphoma.J Clin Oncol. 2001;19:3918–3928.

    Article  Google Scholar 

  54. Grillo-López AJ. Radioimmunotherapy with 90-yttrium Zevalin for indolent or aggressive non-Hodgkin’s lymphomas.Haemato-logica. 2001;86:65–69.

    Google Scholar 

  55. Grillo-López AJ,White CA, Dallaire BK, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma.Curr Pharm Biotechnol. 2000;1:1–9.

    Article  PubMed  Google Scholar 

  56. Grillo-López AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development.Semin Oncol. 2002; 29(suppl 2):105–112.

    Article  PubMed  CAS  Google Scholar 

  57. Grillo-López AJ. Curative therapies for NHL: a question of time! [editorial].Curr Pharm Biotechnol. 2001;2(theme issue).

  58. Fisher R, Gaynor E, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.N Engl J Med. 1993;328: 1002–1006.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neoplastic and Autoimmune Diseases Research Institute, 3797, 92067, Rancho Santa Fe, California, CA, USA

    Antonio J. Grillo-López

Authors
  1. Antonio J. Grillo-López
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio J. Grillo-López.

About this article

Cite this article

Grillo-López, A.J. Monoclonal Antibody Therapy for B-Cell Lymphoma. Int J Hematol 76, 385–393 (2002). https://doi.org/10.1007/BF02982803

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02982803

Key words

Search

Navigation